Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.
Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.
The profit decline resulted from no longer consolidating the results of JBM Healthcare, a Thursday filing with the Hong Kong Exchange said.
The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.
The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.
The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.